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Abstract
Background: The purpose of this study was to examine the acute metabolic effects of a high-
energy drink in healthy, physically-active women.
Methods: Ten women (20.4 ± 0.70 y; 166.9 ± 7.2 cm; 67.0 ± 7.0 kg; 29.6 ± 6.5% body fat)
underwent two testing sessions administered in a randomized and double-blind fashion. Subjects
reported to the laboratory in a 3-hr post-absorptive state and were provided either 140 ml of the
high-energy drink (SUP; commercially marketed as Meltdown RTD™) or placebo (P). Subjects
consumed two 70 ml doses of SUP or P, separated by 30 min and rested in a semi-recumbent
position for 3 hours. Resting oxygen consumption (VO2) and heart rate (HR) were determined
every 5 min during the first 30 min and every 10 min during the next 150 min. Blood pressure (BP)
was determined every 15 min during the first 30 min and every 30 min thereafter. Area under the
curve (AUC) analysis was computed for VO2, whereas a 3-hour average and hourly averages were
calculated for respiratory quotient (RQ), total kcal, HR, BP, and profile of mood states (POMS).
Results: AUC analysis revealed a 10.8% difference (p = 0.03) in VO2 between SUP and P. No
difference in VO2 was seen between the groups in the first hour, but VO2 in SUP was significantly
greater than P in the second (13.9%, p = 0.01) and third hours (11.9%, p = 0.03). A difference (p =
0.03) in energy expenditure was seen between SUP (1.09 ± 0.10 kcal·min-1) and P (0.99 ± 0.09
kcal·min-1) for the 3-hour period. Although no difference in energy expenditure was seen in the
first hour, significant differences between SUP and P were observed in the second (1.10 ± 0.11
kcal·min-1 and 0.99 ± 0.09 kcal·min-1, respectively; p = 0.02) and third hour (1.08 ± 0.11 kcal·min-1
and 0.99 ± 0.09 kcal·min-1, respectively; p = 0.05). Average systolic BP was significantly higher (p =
0.007) for SUP (110.0 ± 3.9 mmHg) compared to P (107.3 ± 4.4 mmHg). No differences were seen
in HR, diastolic BP, or POMS at any time point.
Conclusions:  Results showed a significant increase in energy expenditure in young, healthy
women following an acute ingestion of a high-energy drink.
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Introduction
The overweight and obese population in America has
been steadily increasing for the past 20 years [1,2]. This is
suggested to be related to changes in the quality, quantity,
source of food consumed, and a decrease in levels of phys-
ical activity in Americans [3]. Increased body fat and body
weight are not only problematic for health reasons, but
also lead to a decrease in self-esteem and have detrimental
effects on mood [4]. This epidemic has caused many over-
weight and obese Americans to consume dietary supple-
ments to aid in weight loss. The desire to reduce or control
body fat appears to be one of the primary reasons for the
consumption of energy drinks [5-7].
Energy drinks have been shown, or have been suggested,
to increase alertness, energy, and to counteract fatigue
[8,9]. In addition, energy drinks have been shown to favo-
rably affect specific physiological functions such as lipol-
ysis, substrate utilization, and energy expenditure [10]. As
a result many manufacturers of energy drinks promote
their products as effective agents in reducing body fat, and
they believe that energy drinks should be part of weight
loss programs.
Energy drink supplements often contain several herbal
and botanical compounds that work synergistically to
enhance energy expenditure, reduce body fat, and possi-
bly enhance mood [11]. Caffeine is generally the basic
ingredient in many energy drinks, and has been shown to
be effective in enhancing lipolysis and fat oxidation
[12,13]. When combined with other herbal compounds
and thermogenic agents, caffeine has also been shown to
increase alertness and concentration, improve mood, and
reduce fatigue [9,14,15].
Despite the high frequency of energy drink consumption,
limited studies are available to ascertain the efficacy of
these drinks in young adult populations. In addition, with
the vast amount of energy drinks that are available on the
market containing varying ingredients it becomes difficult
to extrapolate the results of a few studies on the benefits
of all energy drinks. Thus, it becomes imperative to exam-
ine specific combinations of ingredients that are presently
available in these drinks and determine the specific effi-
cacy as it relates to the products contents. The purpose of
this study is to examine the acute effects of a ready to drink
(RTD) supplement marketed as Meltdown RTD™ on rest-
ing oxygen consumption, respiratory quotient, caloric
expenditure, heart rate, blood pressure and mood in
healthy, physically active women.
Methods
Subjects
Ten healthy, physically active women (20.4 ± 0.7 y; 166.9
± 7.2 cm; 67.0 ± 7.0 kg; 29.6 ± 6.5% body fat; BMI 23.9 ±
3.5 kg/m2) underwent two testing sessions administered
in a randomized and double-blind fashion. Subjects were
recruited from The College of New Jersey through
announcements in the Health and Exercise Science
Department. Following an explanation of all procedures,
risks, and benefits associated with the experimental proto-
col, each subject gave her written consent prior to partici-
pating in this study. Subjects completed a medical history
and physical activity questionnaire to determine eligibil-
ity. Subjects who were pregnant, smokers, or taking regu-
lar medication except birth control pills were excluded
from the study. Subjects with any known metabolic or car-
diovascular disease, or psychiatric disorder were also
excluded. Subjects were also required to have been free of
any nutritional supplements or ergogenic aids for 6 weeks
preceding the study, and were asked to refrain from taking
any additional supplement during the course of the study.
Study Design
The study followed a double-blind, crossover design. Sub-
jects reported to the Human Performance Laboratory at
the same time of day on two separate days. Each testing
session was separated by an average of 7 days (7.0 ± 2.8
d). Subjects were instructed to refrain from consuming
any caffeine products on the day of each testing session
and from performing any strenuous physical activity for
the previous 12 hours. In addition, subjects were
instructed to be at least 3 hours post-absorptive state prior
to each trial. During each visit to the laboratory, upon
completing a 30 min resting period, subjects were ran-
domly provided either (140 ml) of the energy drink sup-
plement (SUP), commercially marketed as Meltdown
RTD® (Vital Pharmaceuticals, Inc., Davie, FL) or an equal
amount of placebo (P) as suggested by the manufacturer's
serving recommendation (two 70 ml servings separated
by 30 minutes). On the subject's second visit to the labo-
ratory they were provided with the opposite treatment.
Measurement began immediately after the initial 70 ml
consumption of SUP or P. A half hour following initial
ingestion, measurement was paused as the subjects con-
sumed the remaining 70 ml, and restarted immediately
following consumption. Subjects remained resting in a
semi-recumbent position during the entire measurement
period. They were permitted to read, study, and/or listen
to music following consumption and refrained from
speaking during the study period. The total time of meas-
urement was 3 hours. Oxygen consumption (VO2) and
heart rate (HR) were determined every 5 min during the
first 30 min and every 10 min during the next 150 min.
Blood pressure (BP) was determined every 15 min during
the first 30 min and every 30 min thereafter. The profile of
mood states (POMS), and a questionnaire focusing on
alertness, focus and fatigue were assessed every 30 min.
Metabolic Measures
Immediately following supplement ingestion subjects were
fitted with a Medgraphics preVent™ pneumotach (MedicalLipids in Health and Disease 2009, 8:57 http://www.lipidworld.com/content/8/1/57
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Graphics Corporation, St. Paul, MN) to measure VO2 and
respiratory quotient (RQ) through open-circuit spirometry
using a metabolic measurement cart (CPX Ultima™ series,
Medical Graphics Corporation, St. Paul, MN). Machine cali-
bration was performed prior to each session using a 3-liter
syringe and calibration gases of known concentration of oxy-
gen and carbon dioxide. Measures of VO2, RQ, energy
expenditure, and fat oxidation rate were obtained continu-
ously for the entire 3-hour trial beginning one minute fol-
lowing supplement or placebo consumption. The average
for every 5 min was recorded for the first 30 min, and every
10 min thereafter until 180 min post consumption. HR was
also measured at these time points using a wireless HR mon-
itor (Pacer, Polar CIC, Inc., Port Washington, NY), which
updated HR display every 5 s. BP was measured using a
sphygmomanometer and ausculatory method at 15 min and
30 min post ingestion, and then for every 30 min until data
collection concluded.
Questionnaires
The POMS was administered 7 times during each testing
session. The initial POMS administration was given as the
subject reported to the Human Performance Laboratory,
and every half hour for the three hour period following
supplement ingestion. All questionnaires were performed
under controlled conditions (a quiet room alone with the
investigator) and the same researcher performed all test
administrations.
The POMS consists of 65 words or phrases in a Likert for-
mat questionnaire which provides measures of specific
mood states. It provides measures of tension, depression,
anger, vigor, fatigue and confusion. A total mood score is
computed by subtracting vigor from the sum of the five
other negative measures and adding 100 to avoid a nega-
tive result. McNair et al. [16], has reported internal con-
sistency of measures ranging between 0.85 to 0.95 and
test-retest reliability estimates ranging between 0.65 to
0.74. These lower coefficients of stability are thought to be
indicative of transient and fluctuating characteristics of
mood states. During all test administrations participants
were asked to describe their feelings upon how they were
feeling at that moment.
Subjects were also asked to complete an energy level ques-
tionnaire containing four questions using a 5-point rating
scale. Subjects were asked to rate their energy level, fatigue
level, feelings of alertness and feelings of focus for task
using the following verbal anchors: 1 = very low; 2 = low;
3 = average; 4 = high; 5 = very high. The same researcher
performed all test administrations and tests were con-
ducted under controlled conditions (a quiet room).
Supplement
On each visit subjects ingested either 140 ml of Meltdown
RTD® or a placebo. Meltdown RTD® contains 230 mg of
anhydrous caffeine, and the following herbal and botani-
cal compounds; methyl tetradecylthioacetic acid, yerba
mate extract, methyl-synephrine, methylphenylethylene,
11-hydroxy yohimbine, yohimbine HCL, alpha-yohim-
bine, and methyl-hordenine HCL. The placebo was simi-
lar in appearance and taste to Meltdown RTD®, but
contained only an inert substance.
Statistical Analyses
The area under curve (AUC) for VO2 was calculated by
using a standard trapezoidal technique. RQ, HR, BP and
POMS were averaged over each hour and the entire 180-
minute period. Statistical analysis of the data was accom-
plished using a repeated measures analysis of variance. In
the event of a significant F- ratio, LSD post-hoc tests were
used for pairwise comparisons. AUC analysis and 180-
minute comparisons were analyzed using dependent T-
tests. A criterion alpha level of p ≤ 0.05 was used to deter-
mine statistical significance. All data are reported as mean
± SD. A sample size of 10 subjects provided 88% statistical
power at an α level of 0.05 (two-tailed).
Results
The AUC analysis revealed a 10.8% difference (p = 0.03)
in VO2 between SUP and P for the three hour study
period. No significant differences in resting oxygen con-
sumption were seen in the first hour following ingestion
of the supplement. However, oxygen consumption was
significantly elevated within the second hour (13.9%; p =
0.01) and third hour (11.9%; p = 0.03) following inges-
tion (Figure 1). The average hourly energy expenditure
response to the study protocol is depicted in Figure 2. A
significant difference (p = 0.03) in energy expenditure was
seen between SUP (1.09 ± 0.10 kcal·min-1) and P (0.99 ±
Oxygen Consumption-AUC Figure 1
Oxygen Consumption-AUC. *P < 0.05, between groups; 
3HRAUC = 3-hour average AUC; HR1 = 1st hour; HR2 = 2nd 
hour; HR3 = 3rd hour.Lipids in Health and Disease 2009, 8:57 http://www.lipidworld.com/content/8/1/57
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0.09 kcal·min-1) for the 3-hour period. Although energy
expenditure was not significantly different between SUP
and P in the first hour, significant differences between the
groups were seen in the second hour (1.10 ± 0.11
kcal·min-1 and 0.99 ± 0.09 kcal·min-1, respectively; p =
0.02) and third hour (1.08 ± 0.11 kcal·min-1 and 0.99 ±
0.09 kcal·min-1, respectively; p = 0.05). No significant
change from resting values of RQ were seen between
either SUP (0.86 ± 0.05) or P (0.88 ± 0.06) in the 3-hour
study period.
Blood pressure and heart rate responses to the study pro-
tocol are displayed in Table 1. Significantly higher (p =
0.007) systolic BP (p < 0.01) was observed between SUP
(110.0 ± 3.9 mmHg) and P (107.3 ± 4.4 mmHg) during
the three hour study period. No change from resting levels
and no significant differences were seen between the
groups in HR or diastolic BP at any time point.
No significant differences were seen between SUP and P in
any of the mood states measured during the study (Figure
3). In addition, no change from resting levels in perceived
energy (3.0 ± 0.4 and 3.2 ± 0.6, respectively), fatigue (2.4
± 0.5 and 2.5 ± 0.9, respectively), alertness (3.2 ± 0.3 and
3.2 ± 0.4, respectively), or focus (2.9 ± 0.4 and 3.2 ± 0.5,
respectively) was noted between SUP and P during the
three hour study period.
Discussion
Results of this study support previous research indicating
that the high-energy supplement Meltdown™ can enhance
metabolic rate in healthy, college-aged students [17-20].
Prior studies examined the capsule form of the supple-
ment, whereas this was the first examination of the liquid
formulation. Similar to these investigations, ingestion of
this supplement significantly increased systolic BP, but
values remained within the normal range. In addition, no
changes were noted to heart rate or diastolic BP indicating
that this supplement may not pose a significant cardiovas-
cular risk in apparently healthy subjects.
Previous studies have shown increases in resting energy
expenditure over 2 to 3-hour time periods following caf-
feine ingestion in combination with additional ingredi-
ents including ephedra, black tea, green tea extract, Citrus
aurantium, and yohimbine [17-23]. The common ingredi-
ent found in these studies has been caffeine, which has
been shown to be very effective in elevating energy
expenditure. Caffeine is thought to increase sympathetic
nervous system activity by stimulating the alpha- and
beta-adrenoreceptors, and to induce adenosine antago-
nism, which can lead to increase BP and heart rate
[22,23].
The combination of caffeine and other herbal ingredients
examined in this study resulted in a 10.8% increase in
resting energy expenditure over the 3-hour period. The
increase in energy expenditure for SUP was observed pri-
Caloric Expenditure Figure 2
Caloric Expenditure. *P < 0.05, between groups; 
3HRAUC = 3-hour average AUC; HR1 = 1st hour; HR2 = 2nd 
hour; HR3 = 3rd hour.
Table 1: Average Hourly Cardiovascular Measures
Variable Baseline Hour 1 Hour 2 Hour 3
Heart Rate (b·min-1) SUP 77.7 ± 9.6 77.2 ± 10.3 76.8 ± 9.8 79.0 ± 9.4
P 79.0 ± 11.6 80.6 ± 12.6 78.1 ± 10.5 78.7 ± 11.9
Systolic Blood Pressure (mmHg) SUP 110.0 ± 3.9 * 110.2 ± 4.1 * 112.2 ± 4.9 * 109.1 ± 4.3 *
P 107.3 ± 4.4 108.0 ± 5.0 106.4 ± 5.2 106.0 ± 4.0
Diastolic Blood Pressure (mmHg) SUP 75.1 ± 3.2 75.5 ± 4.0 75.2 ± 3.6 74.9 ± 3.1
P 74.6 ± 3.7 74.1 ± 4.6 73.1 ± 4.9 74.4 ± 3.9
*P < 0.05, between groups; SUP = Supplement; P = PlaceboLipids in Health and Disease 2009, 8:57 http://www.lipidworld.com/content/8/1/57
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marily during the second and third hour after consump-
tion. Due to the manufacturer's serving recommendation,
subjects consumed half (70 ml) of the supplement at
baseline, and the remaining 70 ml after 30 minutes. It is
likely that the thermogenic effect of the energy drink was
delayed as a result of the ingestion pattern employed.
These results also confirm previous findings by others that
showed a delayed thermogenic effect from energy drink
consumption for 30 - 60 minutes following ingestion, and
then an ability to increase energy expenditure for the sub-
sequent 120 minutes [8]. In addition, the results of this
study also show a lower thermogenic effect (~18% differ-
ence) of this particular supplement compared to a previ-
ous study from our laboratory that examined the capsule
form of this supplement [19]. It is possible that mode of
ingestion (liquid versus capsule), stability differences
between the two modes, or ingestion pattern (entire sup-
plement ingested immediately or a staggered ingestion),
may have contributed to the reduced thermogenic
response. The staggered ingestion pattern likely limited
the thermogenic response in the first hour of measure-
ment.
The increase in the metabolic rate is consistent with other
investigations examining caffeine and additional ther-
mogenic agents [17-21,24-26]. In addition, the elevated
systolic BP seen during the SUP treatment is also similar
to other studies examining weight loss supplements con-
taining adrenergic amines [21,25,27]. Synephrine, an
active component of Citrus aurantium, has an adrenergic
effect that may result in appetite suppression, increased
metabolic rate, and lipolysis [28]. Alpha and beta-adren-
ergic drugs have well-documented effects on the cardio-
vascular system, indicating synephrine would have
similar hemodynamic effects [28]. Similar to our findings,
Hofstetter and colleagues [29] reported that synephrine
intake in healthy subjects caused significant elevations in
systolic and mean arterial pressures, while diastolic BP
and heart rate were unchanged.
The findings of this study do not support previous
research from our laboratory that indicated that the com-
bination of yohimbine, yerba mate extract and tetrade-
cylthioacetic acid can enhance utilization of stored fat
[19]. Others have demonstrated that these ingredients,
either by themselves or in combination, are effective in
enhancing lipid metabolism [19,30-34]. The effect of this
combination of ingredients has been realized following
60 minutes after ingestion of the capsule form of this sup-
plement. It is possible that the staggered consumption
pattern may have limited the effectiveness of this supple-
ment regarding fat oxidation within the time frame exam-
ined. Yohimbine's effect may have also been modulated
by its various metabolites within the supplement. Consid-
ering that there are differences in the α-2 adrenoceptor
blocking potency and half-life between the metabolites of
yohimbine [35], the staggered consumption pattern may
have limited the ability to effectively generate a sufficient
stimulus for enhanced lipolysis.
The addition of phenylethylamine as an ingredient was
thought to enhance the mood of subjects using this sup-
plement. Prior research has shown that phenylethylamine
can produce relief of depression among a clinical popula-
tion, even in those that were unresponsive to standard
treatments [36]. The mechanism of action is thought to be
related to the stimulation of dopamine release [37], which
can not only improve mood, but may has also been
shown to reduce appetite [38]. An advantage in the use of
phenylethylamine is thought to be related to the benefi-
cial improvements seen in mood without producing a tol-
erance often associated with amphetamines [36]. The
results of this study however, do not support any role for
phenylethylamine in affecting mood in apparently
healthy, college-aged females consuming an energy drink.
In addition, no difference in alertness, focus and energy
was noted. However, this may have been a function of the
passive nature of this study. Previous studies have shown
that adrenergic stimulators are effective in enhancing
alertness and focus in this age group performing high
intensity activity [9].
In conclusion, the results of this study indicate that acute
ingestion of Meltdown RTD™ increases energy expendi-
ture in young, healthy women. In addition, ingestion of
this supplement increases systolic blood pressure for three
hours following ingestion. However, BP values stayed will
within the normal range. No changes in mood, subjective
feelings of alertness, focus, or energy were seen. Future
research should examine the potential role that chronic
intake of this supplement has on fat loss and body com-
position changes.
Profile of Mood States Figure 3
Profile of Mood States.Lipids in Health and Disease 2009, 8:57 http://www.lipidworld.com/content/8/1/57
Page 6 of 7
(page number not for citation purposes)
Competing interests
Vital Pharmaceuticals. (Davie, FL) provided funding for
this project. All researchers involved independently col-
lected, analyzed, and interpreted the results from this
study and have no financial interests concerning the out-
come of this investigation. Publication of these findings
should not be viewed as endorsement by the investigators,
The College of New Jersey or the editorial board of the
Lipids in Health and Disease.
Authors' contributions
JRH obtained grant funds for project, designed study,
supervised all study recruitment, data/specimen analysis,
statistical analysis and manuscript preparation. SLR was
the lead author, performed data collection and data anal-
ysis. JK, NAR, AC and ADF were co-authors, oversaw all
aspects of study including recruitment, data/specimen
analysis, and manuscript preparation. All authors have
read and approved the final manuscript.
Acknowledgements
This study was funded by Vital Pharmaceuticals, Inc. dba VPX/Meltdown 
RTD. The authors would like to thank Steve Anderson, Adam Gonzalez, 
Neil Kelly and Mike Stec for their contribution to data collection.
References
1. Li C, Ford ES, McGuire LC, Mokdad AH: Increasing trends in
waist circumference and abdominal obesity among U.S.
adults.  Obesity 2007, 15:216-224.
2. Center for Disease Control: State-Specific Prevalence of Obes-
ity Among Adults-United States, 2007.  MMWR 2008,
57:765-768.
3. Yach D, Stuckler D, Brownell KD: Epidemiologic and economic
consequences of the global epidemics of obesity and diabe-
tes.  Nature Med 2006, 12:62-66.
4. Martyn-Nemeth P, Penckofer S, Gulanick M, Velsor-Friedrich B, Bry-
ant FB: The relationships among self esteem, stress, coping,
eating behavior, and depressive mood in adolescents.  Res
Nurs Health 2009, 32:96-109.
5. Bell A, Dorsch KD, McCreary DR, Hovey R: A look at nutritional
supplement use in adolescents.  J Adolesc Health 2004,
34:508-516.
6. Dodge TL, Jaccard JJ: The effect of high school sports participa-
tion on the use of performance-enhancing substances in
young adulthood.  J Adolesc Health 2006, 39:367-373.
7. Hoffman JR, Faigenbaum AD, Ratamess NA, Ross R, Kang J, Tenen-
baum G: Nutritional supplementation and anabolic steroid
use in adolescents.  Med Sci Sports and Exerc 2008, 40:15-24.
8. Smit HJ, Cotton JR, Hughes SC, Rogers PJ: Mood and cognitive
performance effects of "energy" drink constituents: caffeine,
glucose and carbonation.  Nutr Neurosci 2004, 7:127-139.
9. Hoffman JR, Kang J, Ratamess NA, Hoffman MW, Tranchina CP,
Faigenbaum AD: Examination of a high energy, pre-exercise
supplement on exercise performance.  J Internat Soc Sports Nutr
2009, 6:2.
10. Finnegan D: The health effects of stimulant drinks.  Nutr Bull
2003, 28:147-155.
11. Pittler MH, Ernst E: Dietary supplements for body-weight
reduction: a systematic review.  Amer J Clin Nutr 2004,
79:529-536.
12. Acheson KJ, Zahorska-Markiewicz B, Pittet PH, Anantharaman K,
Jéquier E: Caffeine and coffee: their influence on metabolic
rate and substrate utilization in normal and obese individu-
als.  Am J Clin Nutr 1980, 33:989-997.
13. Dulloo AG, Geisler CA, Horton T, Collins A, Miller DS: Normal caf-
feine consumption: Influence on thermogenesis and daily
energy expenditure in lean and postobese human volun-
teers.  Am J Clin Nutr 1989, 49:44-50.
14. Scholey AB, Kennedy DO: Cognitive and physiological effects of
an "energy drink": an evaluation of the whole drink and of
glucose, caffeine, and herbal flavouring fractions.  Psychopharm
2004, 176:320-330.
15. Smith A: Effects of caffeine on human behavior.  Food Chem Tox-
icol 2002, 40:1243-1255.
16. McNair DM, Lorr M, Droppleman LF: Profile of Mood States Man-
ual.  San Diego: Educational and Industrial Testing Service; 1971. 
17. Bloomer RJ, Fisher-Wellman KH, Hammond KG, Schilling BK, Weber
AA, Cole BJ: Dietary supplement increases plasma norepine-
phrine, lipolysis, and metabolic rate in resistance trained
men.  J Intern Soc Sports Nutr 2009, 6:4.
18. Bloomer RJ, Canale RE, Blankenship MM, Hammond KG, Fisher-Well-
man KH, Schilling BK: Effect of the dietary supplement Melt-
down on catecholamine secretion, markers of lipolysis, and
metabolic rate in men and women: a randomized, placebo
controlled, cross-over study.  Lipids Health Dis 2009, 8:32.
19. Hoffman JR, Kang J, Ratamess NA, Rashti SL, Tranchina CP, Faigen-
baum AD: Thermogenic effect of an acute ingestion of a
weight loss supplement.  J Intern Soc Sports Nutr 2009, 6:1.
20. Jitomir J, Nassar E, Culbertson J, Moreillon J, Buford T, Hudson G,
Cooke M, Kreider R, Willoughby DS: The acute effects of the
thermogenic supplement Meltdown on energy expenditure,
fat oxidation, and hemodynamic responses in young, healthy
males.  J Int Sec Sports Nutr 2008, 5:23.
21. Hoffman JR, Kang J, Ratamess NA, Jennings PF, Mangine G, Faigen-
baum AD: Thermogenic effect of nutritionally enriched coffee
consumption.  J Int Sec Sports Nutr 2006, 3:35-41.
22. Belza A, Toubro S, Astrup A: The effect of caffeine, green tea,
and tyrosine on thermogenesis and energy intake.  Eur J Clin
Nutr 2009, 63:57-64.
23. Dulloo AG, Duvet C, Rohrer D, Girardier L, Mensi N, Fathi M, Chan-
tre P, Vandermander J: Efficacy of a green tea extract rich in cat-
echin polyphenols and caffeine in increasing 24-h energy
expenditure and fat oxidation in humans.  Amer J Clin Nutr 1999,
7:1040-1050.
24. Greenway FL, de Jonge L, Blanchard D, Frisard M, Smith SR: Effect
of a dietary herbal supplement containing caffeine and ephe-
dra on weight, metabolic rate, and body composition.  Obes
Res 2004, 12:1152-1157.
25. Haller CA, Jacob P, Benowitz NL: Enhanced stimulant and met-
abolic effects of ephedrine and caffeine.  Clin Pharmacol Ther
2004, 75:259-273.
26. Roberts AT, de Jonge-Levitan L, Parker CC, Greenway FL: The
effect of an herbal supplement containing black tea and caf-
feine on metabolic parameters in humans.  Alt Med Rev 2005,
10:321-325.
27. Vukovich MD, Schoorman R, Heilman C, Jacob P, Benowitz NL: Caf-
feine-herbal ephedra combination increases resting energy
expenditure, heart rate and blood pressure.  Clin Exp Pharmacol
Physiol 2005, 32:47-53.
28. Fugh-Berman A, Myers A: Citrus aurantium, an ingredient of
dietary supplements marketed for weight loss: current sta-
tus of clinical and basic research.  Exper Bio Med 2004,
229:698-704.
29. Hofstetter R, Kreuder J, von Bernuth G: The effect of oxedrine on
the left ventricle and peripheral vascular resistance [English
translation].  Arzneimittelforschung 1985, 35:1844-1846.
30. Galitzky J, Taouis M, Berlan M, Riviere D, Garrigues M, Lafontan M:
Alpha 2-antagonist compounds and lipid mobilization: evi-
dence for a lipid mobilizing effect of oral yohimbine in
healthy male volunteers.  Eur J Clin Invest 1988, 18:587-594.
31. Heck CI, de Mejia EG: Yerba Mate Tea (Ilex paraguariensis): a
comprehensive review on chemistry, health implications,
and technological considerations.  J Food Sci 2007, 72:138-151.
32. Lafontan M, Berlan M, Galitzky J, Montastruc JL: Alpha-2 adreno-
ceptors in lipolysis: alpha 2 antagonists and lipid-mobilizing
strategies.  Am J Clin Nutr 1992, 55(suppl):219-227.
33. Pang J, Choi Y, Park T: Ilex paraguariensis extract ameliorates
obesity induced by high-fat diet: Potential role of AMPK in
the visceral adipose tissue.  Arch Biochem Biophys 2008,
476:178-185.
34. Vaagenes H, Madsen L, Dyroy E, Elhom M, Stray-Pedersen A, Froy-
land L, Lie O, Berge RK: Methylated eicosapentaenoic acid andPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2009, 8:57 http://www.lipidworld.com/content/8/1/57
Page 7 of 7
(page number not for citation purposes)
tetradecylthioacetic acid: effects on fatty acid metabolism.
Biochem Pharmacol 1999, 58:1133-1143.
35. Berlan M, Le Verge R, Galitzky J, Le Corre P: α2-adrenoceptor
antagonist potencies of two hydroxylated metabolites of
yohimbine.  Br J Pharmacol 1993, 108:927-932.
36. Sabelli H, Fink P, Fawcett J, Tom C: Sustained antidepressant
effect of PEA replacement.  J Neuropsychiatry Clin Neurosci 1996,
8:168-171.
37. Nakamura M, Ishii A, Nakahara D: Characterization of β-phe-
nylethylamine-induced monamine release in rat nucleus
accumbens: a microdialysis study.  Eur J Pharmacol 1998,
349:163-169.
38. Dourish CT, Boulton AA: The effects of acute and chronic
administration of beta-phenylethylamine on food intake and
body weight in rats.  Prog Neuropschopharmacol 1981, 5:411-414.